Posts by: David Melamed

News

ImmunoGen has announced a collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co, a subsidiary of Huadong Medicine, to develop and commercialize the ... Read more

November 5, 2020November 5, 2020

First Patient Dosed in Phase 2 Study of Cancer Vaccine Combination in Ovarian Cancer

News

The first patient has been dosed in a Phase 2 extension study investigating the cancer vaccine DSP-7888 (ombipepimut-S) in combination with ... Read more

September 1, 2020September 1, 2020

Organ-on-a-chip Device Shows How Cancer Cells Interact With Platelets to Drive Metastasis

News

To communicate with platelets and start the process of cancer spread, ovarian cancer cells are able to break the barriers of ... Read more

July 14, 2020July 14, 2020

$2.2M Awarded to Collaboration Researching Rare Form of Ovarian Cancer

News

A research collaboration led by the Hudson Institute of Medical Research as been awarded a $2.2-million grant to advance knowledge about ... Read more

April 22, 2020April 22, 2020

First Advanced Cancer Patients Dosed With VT1021 in Trial’s Expansion Phase

News

A Phase 1b/2 trial investigating Vigeo Therapeutics‘ VT1021 as a stand-alone treatment for advanced ovarian cancer and other tumor types has dosed ... Read more

March 2, 2020March 2, 2020

New Blood Test May Aid in Determining Cancerous Ovarian Growths, Study Shows

News

The inflammatory protein interleukin-6 (IL-6) appears at significantly higher levels in the blood of ovarian cancer patients in comparison with women ... Read more

February 19, 2020February 19, 2020

Myriad Asks FDA to Approve myChoice CDx to Find Potential Lynparza Candidates

News

Myriad Genetics submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of its myChoice CDx test to ... Read more